Examples include an engineered human MTSP1 protease targeting C3 as a treatment of age-related macular degeneration (AMD) [8] and the use of ScpA, a bacterial protease specific for C5a, as an intervention in sepsis [9]. This evidence concerns the gene C5 and age-related macular degeneration.